Clinical Trial Update: Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial investigating reducing the number of chemotherapy cycles in combination with pembrolizumab as first-line treatment for PD-L1–positive recurrent or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Institut Claudius Regaud | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: RECRUITING